Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 6/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.34 |
| ▸ | C1S | P09871 | 2/20 | 0.33 |
| ▸ | CFD | P00746 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | KLK1 | P06870 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7336146 | 0.86 | PLAU (0.46) | CYP1A1CYP1B1PLGPLAUPLAT | |
| SCHEMBL7340250 | 0.82 | POLB (0.33) | ALOX5PLGPLAUPLATKLK1 | |
| SCHEMBL7341740 | 0.81 | IAPP (0.36) | PTGS1CYP1A1CYP1B1GAA | |
| SCHEMBL7335720 | 0.79 | PLG (0.34) | CYP1A1CYP1B1PLGPLAUPLAT | |
| SCHEMBL7344167 | 0.79 | TBXAS1 (0.42) | — | |
| SCHEMBL7337460 | 0.76 | PLAU (0.32) | HDAC6PLAUGAA | |
| Trifluoroacetic Acid SCHEMBL7337163 | 0.74 | PLAU (0.56) | ALOX5PTGS1PTGS2CYP1A1CYP1A2 | |
| SCHEMBL7345650 | 0.74 | F9 (0.40) | PLGPLAU | |
| SCHEMBL7336751 | 0.72 | LMNA (0.37) | CYP1A1CYP1A2CYP1B1GAA | |
| SCHEMBL7499445 | 0.72 | PLAU (0.35) | PTGS2CYP1A1CYP1B1PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | disclosed |
| US-6284796-B1 | NAPHTHAMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
| EP-1000018-A2 | UROKINASE INHIBITORS | Abbott Laboratories (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999005096-A2 | UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049374-A1 | Urokinase inhibitors | SERPINE1, PLAU, SERPINB1 | ALOX5 583/4885PTGS1 198/4885PTGS2 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.